Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2011 - 2026)

Arbutus Biopharma (ABUS) has reported Total Non-Current Liabilities for 16 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 69.33% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 69.33% YoY) and the FY2025 annual result came in at $9.6 million, down 60.0% from the prior year.
• Total Non-Current Liabilities eased to $8.4 million in Q1 2026 per ABUS's latest filing, from $9.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ABUS reached as high as $55.6 million in Q1 2022 and fell as low as $8.4 million in Q1 2026.
• A 5-year average of $29.5 million and a median of $29.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 336.88% — and 2026, when it tumbled 69.33%.
• Year by year, Total Non-Current Liabilities stood at $48.2 million in 2022, then slumped by 36.14% to $30.8 million in 2023, then slipped by 21.66% to $24.1 million in 2024, then plunged by 60.0% to $9.6 million in 2025, then decreased by 13.1% to $8.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.4 million, $9.6 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.